ENTRY       D10912                      Drug
NAME        Brazikumab (USAN/INN)
SEQUENCE    (Heavy chain)
            QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNEYY
            ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDR GYTSSWYPDA FDIWGQGTMV
            TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV
            LQSSGLYSLS SVVTVPSSNF GTQTYTCNVD HKPSNTKVDK TVERKCCVEC PPCPAPPVAG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN
            STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ VYTLPPSREE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM LDSDGSFFLY SKLTVDKSRW
            QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
            (Light chain)
            QSVLTQPPSV SGAPGQRVTI SCTGSSSNTG AGYDVHWYQQ VPGTAPKLLI YGSGNRPSGV
            PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDSSLSGW VFGGGTRLTV LGQPKAAPSV
            TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV KAGVETTTPS KQSNNKYAAS
            SYLSLTPEQW KSHRSYSCQV THEGSTVEKT VAPTECS
            (Disulfide bridge: H22-H96, H138-L216, H151-H207, H226-H'226, H227-H'227, H230-H'230, H233-H'233, H264-H324, H370-H428, H'22-H'96, H'151-H'207, H'370-H'428, L22-L90, L139-L198, L'22-L'90, L'139-L'198)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
EFFICACY    Anti-inflammatory, Anti-IL-23 antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of Crohn's disease
TARGET      IL23A [HSA:51561] [KO:K05426]
  PATHWAY   hsa04060(51561)  Cytokine-cytokine receptor interaction
BRITE       Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10912  Brazikumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL23A
                 D10912  Brazikumab (USAN/INN)
DBLINKS     CAS: 1610353-18-8
            PubChem: 342581769
///
